Module

Targeting Multiple Pathways in the Treatment of Cancer

Source: Translating Science Into Clinical Practice: Recent Lessons in EGFR Inhibition, Multitargeted TKIs, and the Tumor Microenvironment

Targeting Multiple Pathways in the Treatment of Cancer

Program Director: Ezra E. W. Cohen, MD, FRCPC

Faculty:

Manuel Hidalgo, MD, PhD

CME CREDIT INFORMATION

Release Date: 08/01/08

Expiration Date: 07/31/09

Physicians: maximum of 0.5 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the challenges associated with developing effective cancer therapies targeting the epidermal growth factor receptor
Discuss the potential advantages and disadvantages of multitargeted tyrosine kinase inhibitors
Explain how the tumor microenvironment could be a target for cancer therapy

Topics covered include:

Introduction: Cancer Targets and Drugs
EGFR-Targeted Therapies
Multitargeted Tyrosine Kinase Inhibitors
Tumor/Bone Microenvironment
References

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.